MK-677 vs RAD-140: Ibutamoren vs Testolone Research Comparison
MK-677 and RAD-140 are frequently discussed within the same research-compound category, but they are not members of the same pharmacological class. Their molecular targets, signalling pathways and experimental research endpoints are fundamentally different.
MK-677, also known as ibutamoren, is a non-peptide growth hormone secretagogue that interacts with the ghrelin receptor. RAD-140, commonly called Testolone, is a non-steroidal selective androgen receptor modulator, or SARM.
Understanding this distinction is essential when interpreting laboratory findings. Grouping both compounds together simply because they appear in similar research collections can obscure major differences in receptor activity, biological signalling and evidence quality.
This research article compares MK-677 vs RAD-140, explains why MK-677 is not a SARM and identifies the principal variables researchers may consider when examining these compounds.
What Is MK-677 Ibutamoren?
MK-677 is a synthetic small-molecule compound developed for research involving growth hormone secretagogue receptor pathways. It is also identified in scientific literature as ibutamoren, MK-0677 and L-163,191.
Despite frequently appearing alongside SARMs, MK-677 does not selectively activate the androgen receptor. It instead acts as an agonist of the growth hormone secretagogue receptor type 1a, abbreviated GHSR-1a.
This receptor is also commonly called the ghrelin receptor. Its activation can influence intracellular signalling associated with growth hormone release, appetite regulation, energy balance and downstream insulin-like growth factor activity.
Principal MK-677 research characteristics include:
Non-peptide small molecule, Growth hormone secretagogue, Ghrelin receptor agonist, GHSR-1a signalling, Growth hormone pathway research, IGF-1 pathway investigation, Metabolic-marker assessment, Body-composition research.
Calling MK-677 a peptide would also be technically inaccurate. Although the compound is studied in pathways associated with peptide hormones, its chemical structure is not a chain of amino acids.
Its research classification should therefore be clearly stated as a non-peptide growth hormone secretagogue rather than a peptide or SARM.
What Is RAD-140 Testolone?
RAD-140, also known as Testolone, is a synthetic non-steroidal selective androgen receptor modulator. Unlike MK-677, it was designed to interact directly with the androgen receptor.
The androgen receptor is an intracellular nuclear receptor involved in regulating gene transcription. When an appropriate ligand binds to it, the receptor undergoes structural changes and participates in the expression of androgen-responsive genes.
RAD-140 has attracted experimental interest because its receptor activity may vary between tissues. This concept of tissue selectivity is central to SARM research, although the degree of selectivity observed can depend on the experimental model, concentration and endpoints being measured.
Principal RAD-140 research characteristics include:
Non-steroidal androgen receptor ligand, Selective androgen receptor modulation, Androgen-responsive gene expression, Tissue-selectivity research, Myogenic signalling investigation, Lean-tissue endpoints, Preclinical pharmacology, Receptor-binding assessment.
RAD-140 is therefore correctly classified within the SARM family. This classification separates it from MK-677, which does not rely on androgen-receptor activation as its principal mechanism.
MK-677 vs RAD-140—How Do Their Mechanisms Differ?
The central distinction between MK-677 and RAD-140 is the receptor system through which each compound produces experimental activity.
MK-677 interacts with GHSR-1a, a cell-surface G protein-coupled receptor. Receptor activation can initiate intracellular signalling involving phospholipase C, inositol trisphosphate, diacylglycerol and calcium mobilisation. These processes are associated with growth hormone secretagogue activity and downstream endocrine markers.
RAD-140 interacts with the androgen receptor, an intracellular receptor capable of regulating gene transcription. After ligand binding, androgen-receptor signalling may influence cellular programmes associated with protein synthesis, tissue differentiation and myogenic activity.
The principal mechanistic differences are:
MK-677 target—GHSR-1a ghrelin receptor, RAD-140 target—Androgen receptor, MK-677 pathway—Growth hormone secretagogue signalling, RAD-140 pathway—Androgen-responsive transcription, MK-677 classification—Non-peptide small molecule, RAD-140 classification—Non-steroidal SARM.
This means the compounds should not be treated as interchangeable research materials. Even when a study measures similar downstream outcomes, such as body-composition or lean-tissue variables, the biological route being investigated remains different.
MK-677 research is principally associated with the growth hormone and IGF-1 axis. RAD-140 research is instead centred on androgen-receptor signalling and the transcriptional processes influenced by that receptor.
Which Research Endpoints Are Used to Compare MK-677 and RAD-140?
A scientifically useful MK-677 vs RAD-140 comparison should focus on measurable research endpoints rather than presenting either compound as universally superior.
MK-677 research commonly focuses on growth hormone and IGF-1 pathway markers. Depending on the experimental design, investigators may also monitor metabolic activity, appetite-related signalling, glucose regulation, insulin markers and changes in body-composition variables.
RAD-140 studies concentrate more directly on androgen-receptor activity. Researchers may examine receptor binding, transcriptional responses, tissue selectivity, protein-expression markers and changes within experimental muscle or bone models.
Common MK-677 research endpoints include:
Growth hormone markers, IGF-1 markers, Ghrelin-receptor activity, Appetite-related signalling, Energy-balance pathways, Glucose markers, Insulin markers, Body-composition variables.
Common RAD-140 research endpoints include:
Androgen-receptor binding, Receptor selectivity, Gene-transcription activity, Myogenic markers, Protein-expression pathways, Lean-tissue variables, Bone-model endpoints, Tissue-dependent responses.
Experimental concentration, exposure duration, model selection, control conditions and analytical methodology can all affect the observed results. Findings from one experimental system should not automatically be applied to another.
Product quality also matters when interpreting research data. Identity, purity and concentration must be established before biological observations can be reliably attributed to the compound being studied.
Important analytical variables include:
Solution appearance, Measured pH, Compound identity, Purity profile, Aggregation, Degradation products, Concentration, Stability over time.
Why Is MK-677 Commonly Mistaken for a SARM?
MK-677 is frequently mistaken for a SARM because research suppliers and online discussions often place it in the same broad category as RAD-140, LGD-4033 and other androgen-receptor compounds.
Commercial grouping, however, does not determine scientific classification.
A genuine SARM must modulate androgen-receptor activity selectively. MK-677 does not meet that definition because its principal target is GHSR-1a. It belongs to the growth hormone secretagogue research category instead.
The confusion may also result from overlapping experimental interests. MK-677 and certain SARMs are both discussed in relation to body composition, lean tissue and metabolic research. Similar endpoints do not mean the compounds share the same receptor or mechanism.
Compounds frequently grouped with SARMs despite belonging to other classes include:
MK-677—Growth hormone secretagogue, SR-9009—REV-ERB agonist research compound, SR-9011—REV-ERB agonist research compound, GW-501516—PPARδ agonist research compound.
Accurate terminology improves scientific communication and prevents search-led category labels from being mistaken for pharmacological definitions.
For search clarity, MK-677 may be discussed in a SARMs research article, but the content should explicitly explain that ibutamoren is not a selective androgen receptor modulator.
Conclusion
MK-677 and RAD-140 belong to different research classifications and act through separate biological pathways.
MK-677 is a non-peptide growth hormone secretagogue and GHSR-1a agonist. Its research profile centres on ghrelin-receptor signalling, growth hormone markers, IGF-1 pathways and related metabolic variables.
RAD-140 is a non-steroidal SARM. Its experimental activity centres on androgen-receptor binding, tissue-selective signalling and androgen-responsive gene transcription.
Although MK-677 and RAD-140 may be examined in relation to some overlapping endpoints, this does not make them mechanistically equivalent. Similar changes in a downstream measurement can arise through entirely different receptors and signalling systems.
Neither compound can be declared universally superior on scientific grounds. The appropriate research material depends on the receptor system, biological question, experimental model and analytical endpoints being investigated.
The most accurate MK-677 vs RAD-140 comparison is therefore not which compound is “better,” but how two distinct mechanisms can be studied in relation to different—and occasionally overlapping—research outcomes.
Continue Exploring...
MK-677 Ibutamoren Research Compound
Explore MK-677 Ibutamoren at BioPlex Peptides ⟶
RAD-140 Testolone Research Compound
Explore RAD-140 Testolone at BioPlex Peptides ⟶
MK-677 Ibutamoren Research Overview
Read the MK-677 Ibutamoren Research Overview ⟶
Why MK-677 Is Not a SARM
Read Why MK-677 Ibutamoren Is Not a SARM ⟶
MK-677 vs MK-777 Research Comparison
Read the MK-677 vs MK-777 Research Comparison ⟶
SARMs and Related Research Compounds
Explore the BioPlex SARMs Research Collection ⟶
Independent Compound Testing
Explore Independent Testing with Vanguard Laboratory ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
